Previous studies have reached conflicting results regarding the relationship between obesity and diabetic retinopathy (DR).
An expanded indication for aflibercept injection (Eylea, Regeneron) is now approved by the FDA to treat all stages of diabetic retinopathy (DR).
“Laser still plays a very important role in the treatment of diabetic macular edema (DME) despite our reliance on anti-vascular endothelial drugs,” said Elias Reichel, MD.
The worldwide incidence of diabetes has been increasing markedly, and by 2014 it had increased to 422 million individuals from 108 million only 34 years previously.
Study: AI can detect swelling, severity of that swelling in macula of patients with diabetes
With the recent surge in artificial intelligence (AI) and machine learning, ophthalmology is already seeing the benefits.
When it comes to questions about the need for laser in diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR), the answers are “yes” and “no,” depending on the clinical scenario, said John Wells, MD.
Anti-vascular endothelial growth factor (VEGF) therapy is a viable alternative to panretinal photocoagulation (PRP) in eyes with proliferative diabetic retinopathy (PDR).